Abstract:Abstract Aryl hydrocarbon receptor(AhR) is a ligand-dependent transcription factor that regulates the activity of innate and adaptive immune cells subsequent to binding of numerous endogenous and exogenous ligands. Recently, kynurenine (Kyn), a tryptophan metabolite, has been identified as the most prominent endogenous ligand of AhR, which is constantly secreted into the tumor microenvironment by cancer cells via IDO1 and TDO2. As this secretion is known to cause a broad immunosuppression, AhR is considered to be a central mediator of suppressing immune responses, thereof, a novel target for cancer immunotherapy. In this study, we have discovered a novel small molecule AhR antagonist, DA-4505, and investigated whether it can pursue the restoration of functionally suppressed immune cells in the tumor microenvironment, then, achieve a consequent anti-tumor effect specifically via altering various aspects of tumor microenvironment. DA-4505, AhR antagonist, exhibited high potency (IC50=3 nM) and showed comparable antagonism to Compound B (an AhR antagonist drug candidate being studied in the clinical phase) in both human and mouse hepatocytes. Furthermore, DA-4505 showed superior alleviating activity on benzo[a]pyrene and 2,3,7,8-tetrachlordibenzodioxin (TCDD, an AhR ligand) induced CYP1A1 mRNA level compared to Compound B in mouse livers. Similarly, DA-4505 treatment presented comparable or even better recovery effect on TNF production under Kyn-induced immunosuppressive condition in monocytes of mouse and human compared to Compound B. DA-4505 dose-dependently enhanced activation of human CD8+ T cells comparable to Compound B and rescued IL-2 and IFNγ production under Kyn treated condition. Moreover, DA-4505 specifically polarized macrophages towards inflammatory macrophage phenotype (M1).Oral administration of DA-4505 induced a significant tumor growth inhibition in several murine syngeneic mouse models and was synergistic in combination with anti-PD1 antibody. DA-4505 enhanced the infiltration of M1-macrophage and CD8+ T cells while suppressed the infiltration of M2-macrophage and Treg, thus, presenting anti-tumor effect. Specifically, we confirmed that the anti-tumor effect of DA-4505 is CD8+ T cell-dependent by CD8+ T cell depleted MC38 mouse model. Taken together, our result showed that DA-4505, AhR antagonist, presented its anti-tumor effects in two distinctive but cooperative way into some extent. Firstly, DA-4505 activated stimulatory immune cells such as monocytes, dendritic cells (DC) and effector T cells. Secondly, DA-4505 reduced the immunosuppressive mechanisms by regulating Treg and M2-macrophage. Thus, our data demonstrate the potential of AhR as a promising therapeutic target for cancer immunotherapy as well as proposing DA-4505 as a novel therapeutic agent for both mono and aPD-1 combinatory therapeutic scheme. Citation Format: Daewon Cha, Dajeong Kim, Jongho Cho, Chaelim Ryu, Hyeon Uk Jeong, Dae Young Lee, Kyu-Hwan Kim, Sunghwa Kim, Jee-Heun Kim, Taedong Han, Hyounmie Doh. Anti-tumor effect of DA-4505, a novel AhR antagonist as an immunotherapy in the tumor microenvironment. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5099.

Discovery of Natural Ah Receptor Antagonists from Salvia miltiorrhiza Bunge and Synthesis of Analogs for Tumor Immunotherapy

Discovery and Biological Evaluation of Tanshinone Derivatives As Potent Dual Inhibitors of Indoleamine 2, 3-Dioxygenase 1 and Tryptophan 2, 3-Dioxygenase

Small Molecule Inhibits Activity of Scavenger Receptor A: Lead Identification and Preliminary Studies

From farm to pharma: Investigation of the therapeutic potential of the dietary plants Apium graveolens L., Coriandrum sativum, and Mentha longifolia, as AhR modulators for Immunotherapy

Design, Syntheses and Biological Evaluation of Natural Product Aiphanol Derivatives and Analogues: Discovery of Potent Anticancer Agents

Tanshinone IIA: New Perspective on the Anti-Tumor Mechanism of A Traditional Natural Medicine.

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy

Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone

Discovery of tert-amine-based RORγt agonists.

Identification of diterpenoids from Salvia castanea Diels f. tomentosa Stib and their antitumor activities

Research and Development of Natural Product Tanshinone I: Pharmacology, Total Synthesis, and Structure Modifications

Abstract 5099: Anti-tumor effect of DA-4505, a novel AhR antagonist as an immunotherapy in the tumor microenvironment

Label-free cell phenotypic profiling of histamine H4R receptor and discovery of non-competitive H4R antagonist from natural products

Discovery of Betulinaldehyde As a Natural RORγt Agonist.

In Silico Comparative Molecular Docking Analysis And Analysis Of The Anti-Inflammatory Mechanisms Of Action Of Tanshinone From Salvia Miltiorrhiza

Design, Synthesis and Biological Evaluation of Tetrazole-Containing RXRα Ligands As Anticancer Agents.

Discovery and development of natural product oridonin-inspired anticancer agents

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Discovery and Development of Natural Product Oridonin-Inspired Anticancer Agents.

Discovery, synthesis and biological evaluation of novel isoquinoline derivatives as potent indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase dual inhibitors

Discovery of <i>tert</i>-amine-based RORt agonists